Literature DB >> 11882908

MUC1 mucin and carbohydrate associated antigens as tumor markers in head and neck squamous cell carcinoma.

M V Croce1, M E Rabassa, M R Price, A Segal-Eiras.   

Abstract

UNLABELLED: An immunological analysis to study MUC1 mucin core protein and carbohydrate associated antigens as tissue tumor markers in head and neck carcinoma was performed. Twenty nine patients with the following tumor localizations were included: tongue (n=10), larynx (n=8), oral cavity (n=4), maxillary sinus (n=3), tonsillar ring (n=3) and pharynx (n=1); seven samples of epithelium obtained from normal organs at the same localizations were studied as controls. Immunohistochemical analysis was performed following standard procedures and reaction was graded according to staining intensity and distribution. From each tissue section, membrane, cytoplasmic and nuclear moieties were obtained by differential centrifugation with subsequent fractionation by density gradient centrifugation (6M guanidium chloride-CsCl); subcellular moieties and CsCl derived fractions were analyzed by immunoblotting. Monoclonal antibodies (MAbs) reacting with the core protein of MUCI (C595) and associated carbohydrate antigens were: Tn, 83D4 MAb; Lewis y antigen (Le y), C14 MAb; Lewis x antigen (Le x), KM380 MAb and sialyl Lewis x (sLe x), KM93 MAb. Statistical analysis was undertaken by Spearman rank correlation. In tumor samples, the immunohistochemical identification of MUCl core protein and associated antigens was extended; differences were found in the pattern and intensity of expression; results were corroborated by immunoblotting although in a few samples there was not coincidence between both methods. Localization, tumor mass or node involvement did not show significant differences for any of the antigens studied.
CONCLUSIONS: 1) head and neck carcinoma expressed MUCI and associated carbohydrate antigens in high levels; 2) no relationship between antigenic expression and tumor status was found.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11882908     DOI: 10.1007/bf03032385

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  34 in total

1.  Detection and isolation of MUC1 mucin from larynx squamous cell carcinoma.

Authors:  M V Croce; M R Price; A Segal-Eiras
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

2.  Immunohistochemical study of MUC1 mucin in premalignant oral lesions and oral squamous cell carcinoma: association with disease progression, mode of invasion, and lymph node metastasis.

Authors:  T Nitta; K Sugihara; S Tsuyama; F Murata
Journal:  Cancer       Date:  2000-01-15       Impact factor: 6.860

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Complexity of expression of antigenic determinants, recognized by monoclonal antibodies HMFG-1 and HMFG-2, in normal and malignant human mammary epithelial cells.

Authors:  J Burchell; H Durbin; J Taylor-Papadimitriou
Journal:  J Immunol       Date:  1983-07       Impact factor: 5.422

5.  A monoclonal antibody against human colonic adenoma recognizes difucosylated Type-2-blood-group chains.

Authors:  A Brown; T Feizi; H C Gooi; M J Embleton; J K Picard; R W Baldwin
Journal:  Biosci Rep       Date:  1983-02       Impact factor: 3.840

6.  Selection of carbohydrate antigens in human epithelial ovarian cancers as targets for immunotherapy: serous and mucinous tumors exhibit distinctive patterns of expression.

Authors:  M F Federici; V Kudryashov; P E Saigo; C L Finstad; K O Lloyd
Journal:  Int J Cancer       Date:  1999-04-12       Impact factor: 7.396

7.  Altered MUC1 and MUC2 glycoprotein expression in laryngeal cancer.

Authors:  J P Jeannon; F W Stafford; J V Soames; J A Wilson
Journal:  Otolaryngol Head Neck Surg       Date:  2001-02       Impact factor: 3.497

8.  Preoperative serum levels of sialyl Lewis(a), sialyl Lewis(x), and sialyl Tn antigens as prognostic markers after curative resection for colorectal cancer.

Authors:  T Nakagoe; T Sawai; T Tsuji; M A Jibiki; A Nanashima; H Yamaguchi; T Yasutake; N Kurosaki; H Ayabe; K Arisawa
Journal:  Cancer Detect Prev       Date:  2001

9.  Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells.

Authors:  K R Jerome; D L Barnd; K M Bendt; C M Boyer; J Taylor-Papadimitriou; I F McKenzie; R C Bast; O J Finn
Journal:  Cancer Res       Date:  1991-06-01       Impact factor: 12.701

10.  Immunohistochemical detection of CEA, CA19-9, and DF3 in esophageal carcinoma limited to the submucosal layer.

Authors:  Y Ikeda; H Kuwano; M Ikebe; K Baba; Y Toh; Y Adachi; K Sugimachi
Journal:  J Surg Oncol       Date:  1994-05       Impact factor: 3.454

View more
  15 in total

1.  Influence of sialic acid removal on MUC1 antigenic reactivity in head and neck carcinoma.

Authors:  María V Croce; Martín E Rabassa; Adrián Pereyra; Amada Segal-Eiras
Journal:  Pathol Oncol Res       Date:  2005-07-01       Impact factor: 3.201

Review 2.  Lewis x is highly expressed in normal tissues: a comparative immunohistochemical study and literature revision.

Authors:  María V Croce; Marina Isla-Larrain; Martín E Rabassa; Sandra Demichelis; Andrea G Colussi; Marina Crespo; Ezequiel Lacunza; Amada Segal-Eiras
Journal:  Pathol Oncol Res       Date:  2007-07-03       Impact factor: 3.201

3.  Tumor biomarker glycoproteins in the seminal plasma of healthy human males are endogenous ligands for DC-SIGN.

Authors:  Gary F Clark; Paola Grassi; Poh-Choo Pang; Maria Panico; David Lafrenz; Erma Z Drobnis; Michael R Baldwin; Howard R Morris; Stuart M Haslam; Sophia Schedin-Weiss; Wei Sun; Anne Dell
Journal:  Mol Cell Proteomics       Date:  2011-10-10       Impact factor: 5.911

4.  Conjunctival 'mucoepidermoid carcinoma' revisited: a revision of terminology, based on morphologic, immunohistochemical and molecular findings of 14 cases, and the 2018 WHO Classification of Tumours of the Eye.

Authors:  Hardeep S Mudhar; Tatyana Milman; Paul J L Zhang; Carol L Shields; Ralph C Eagle; Sara E Lally; Jerry A Shields; Sachin M Salvi; Paul A Rundle; Jennifer Tan; Ian G Rennie
Journal:  Mod Pathol       Date:  2020-01-13       Impact factor: 7.842

5.  Lewis x Antigen is Associated to Head and Neck Squamous Cell Carcinoma Survival.

Authors:  Martín E Rabassa; Adrian Pereyra; Liliana Pereyra; Amada Segal-Eiras; Martín C Abba; Maria V Croce
Journal:  Pathol Oncol Res       Date:  2017-07-05       Impact factor: 3.201

Review 6.  What role do mucins have in the development of laryngeal squamous cell carcinoma? A systematic review.

Authors:  Fabian Sipaul; Martin Birchall; Anthony Corfield
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-04-28       Impact factor: 2.503

7.  Potential ferroptosis-related diagnostic and prognostic biomarkers in laryngeal cancer.

Authors:  Zao Ji; Zhiyao Fang; Xue Dong; Jia Wang; Xianyao Wan; Aihui Yan
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-07-12       Impact factor: 3.236

8.  Effective antitumor therapy based on a novel antibody-drug conjugate targeting the Tn carbohydrate antigen.

Authors:  Christine Sedlik; Adèle Heitzmann; Sophie Viel; Rafik Ait Sarkouh; Cornélie Batisse; Frédéric Schmidt; Philippe De La Rochere; Nathalie Amzallag; Eduardo Osinaga; Pablo Oppezzo; Otto Pritsch; Xavier Sastre-Garau; Pascale Hubert; Sebastian Amigorena; Eliane Piaggio
Journal:  Oncoimmunology       Date:  2016-04-22       Impact factor: 8.110

9.  MUC1 expression and anti-MUC1 serum immune response in head and neck squamous cell carcinoma (HNSCC): a multivariate analysis.

Authors:  Martín E Rabassa; María V Croce; Adrián Pereyra; Amada Segal-Eiras
Journal:  BMC Cancer       Date:  2006-10-25       Impact factor: 4.430

10.  Aptamer-guided DNA tetrahedron as a novel targeted drug delivery system for MUC1-expressing breast cancer cells in vitro.

Authors:  Bindong Dai; Yan Hu; JinHong Duan; Xian-Da Yang
Journal:  Oncotarget       Date:  2016-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.